Suivant

Lecture automatique

MARS: mutation-adjusted risk score for advanced systemic mastocytosis

1 Vues • 07/09/23
Partager
Intégrer
administrator
administrator
Les abonnés
0

Andreas Reiter, MD, University Medical Centre, Mannheim, Germany, discusses how a mutation-adjusted risk score (MARS) may improve treatment stratification for advanced systemic mastocytosis (AdvSM). This interview took place at the Myeloproliferative Neoplasms Advances Day 2019 in London, UK.

Montre plus
0 commentaires sort Trier par
Commentaires de Facebook

Suivant

Lecture automatique